Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.79 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518698 | 0.88 | MAPK10 (1.00) | MAPK10MAPK9MAPK8ALOX5LOXL2 | |
| SCHEMBL4020743 | 0.85 | MAPK10 (0.81) | MAPK10MAPK9MAPK8ALOX5LOXL2 | |
| SCHEMBL2881183 | 0.84 | MAPK10 (0.76) | MAPK10MAPK9MAPK8LOXL2SMN1; SMN2 | |
| SCHEMBL2883411 | 0.84 | MAPK10 (0.73) | MAPK10MAPK9MAPK8ALOX5LOXL2 | |
| SCHEMBL4023709 | 0.84 | MAPK10 (0.78) | MAPK10MAPK9MAPK8ALOX5LOXL2 | |
| SCHEMBL1518642 | 0.83 | MAPK10 (1.00) | MAPK10MAPK9MAPK8ALOX5LOXL2 | |
| SCHEMBL2886417 | 0.83 | MAPK10 (0.81) | MAPK10MAPK9MAPK8ALOX5LOXL2 | |
| SCHEMBL4019069 | 0.82 | MAPK10 (0.73) | MAPK10MAPK9MAPK8SMN1; SMN2NPC1 | |
| SCHEMBL4020500 | 0.82 | MAPK10 (0.73) | MAPK10MAPK9MAPK8SMN1; SMN2NPC1 | |
| SCHEMBL4022971 | 0.82 | MAPK10 (0.84) | MAPK10MAPK9MAPK8NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | claimed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | claimed |
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MERCK SERONO SA (CH) | 2003-08-28 | — | — | US | claimed |
| US-7776854-B2 | Benzazole derivatives for the treatment of scleroderma | MERCK SERONO SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | disclosed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | disclosed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | disclosed |
| EP-1450792-B1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA | APPLIED RESEARCH SYSTEMS (AN) | 2006-09-27 | — | — | EP | disclosed |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-06-02 | — | — | US | disclosed |
| EP-1450792-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-01 | — | — | EP | disclosed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | disclosed |
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MERCK SERONO SA (CH) | 2003-08-28 | — | — | US | disclosed |
| WO-2003047570-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-06-12 | — | — | WO | disclosed |
| EP-1110957-A1 | Benzazole derivatives and their use as JNK modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MAPK1, MAPK3, MAPKAPK2 | MAPK10 46/4885MAPK9 24/4885MAPK8 10/4885 |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | MAPK10 3/4885MAPK9 28/4885MAPK8 12/4885 |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | SMAD3, SQOR, TNNI3 | MAPK10 3441/4885MAPK9 2042/4885MAPK8 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.